Exosomal biomarkers in Down syndrome and Alzheimer's disease

Every person with Down syndrome (DS) has the characteristic features of Alzheimer's disease (AD) neuropathology in their brain by the age of forty, and most go on to develop AD dementia. Since people with DS show highly variable levels of baseline function, it is often difficult to identify ear...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:FREE RADICAL BIOLOGY AND MEDICINE 2018-01, Vol.114, p.110-121
Hauptverfasser: Hamlett, Eric D., Ledreux, Aurélie, Potter, Huntington, Chial, Heidi J., Patterson, David, Espinosa, Joaquin M., Bettcher, Brianne M., Granholm, Ann-Charlotte
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 121
container_issue
container_start_page 110
container_title FREE RADICAL BIOLOGY AND MEDICINE
container_volume 114
creator Hamlett, Eric D.
Ledreux, Aurélie
Potter, Huntington
Chial, Heidi J.
Patterson, David
Espinosa, Joaquin M.
Bettcher, Brianne M.
Granholm, Ann-Charlotte
description Every person with Down syndrome (DS) has the characteristic features of Alzheimer's disease (AD) neuropathology in their brain by the age of forty, and most go on to develop AD dementia. Since people with DS show highly variable levels of baseline function, it is often difficult to identify early signs of dementia in this population. The discovery of blood biomarkers predictive of dementia onset and/or progression in DS is critical for developing effective clinical diagnostics. Our recent studies show that neuron-derived exosomes, which are small extracellular vesicles secreted by most cells in the body, contain elevated levels of amyloid-beta peptides and phosphorylated-Tau that could indicate a preclinical AD phase in people with DS starting in childhood. We also found that the relative levels of these biomarkers were altered following dementia onset. Exosome release and signaling are dependent on cellular redox homeostasis as well as on inflammatory processes, and exosomes may be involved in the immune response, suggesting a dual role as both triggers of inflammation in the brain and propagators of inflammatory signals between brain regions. Based on recently reported connections between inflammatory processes and exosome release, the elevated neuroinflammatory state observed in people with DS may affect exosomal AD biomarkers. Herein, we discuss findings from studies of people with DS, people with DS and AD (DS-AD), and mouse models of DS showing new connections between neuroinflammatory pathways, oxidative stress, exosomes, and exosome-mediated signaling, which may inform future AD diagnostics, preventions, and treatments in the DS population as well as in the general population. [Display omitted] •Exosome technology can detect AD biomarkers decades prior to the onset of symptoms.•Exosome signaling and release are affected by both oxidative homeostasis and inflammation.•Exosomes may deliver therapies targeting oxidative stress, inflammation, and brain pathology.
doi_str_mv 10.1016/j.freeradbiomed.2017.08.028
format Article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_494198</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S089158491730744X</els_id><sourcerecordid>1937527248</sourcerecordid><originalsourceid>FETCH-LOGICAL-c579t-76b19230b64deb02fabc469ae856a2d54ef71be685739a3eb02879dcdac1cda93</originalsourceid><addsrcrecordid>eNqNkc1uEzEUhS0EomnhFdBILGAzg3_HtkCVqpK2SJXYwNry2Heo08k42ElLefp6mrSQBRIb27K_c86VD0JvCW4IJu2HRdMngGR9F-ISfEMxkQ1WDabqGZoRJVnNhW6foxlWmtRCcX2ADnNeYIy5YOolOqBKKSpVO0Of5r9ijks7VJObTdeQchXG6nO8Hat8N_pUMio7-upk-H0FYQnpXa58yGAzvEIvejtkeL3bj9D3s_m304v68uv5l9OTy9oJqde1bDuiKcNdyz10mPa2c7zVFpRoLfWCQy9JB60SkmnLJkRJ7Z23jpRFsyNUb33zLaw2nVmlUEa9M9EGs7u6LicwXHOiVeH1P_lViv6P6FFImGSCckaK9nirLUD5XQfjOtlh32LvZQxX5ke8MS1hAj-Ev98ZpPhzA3ltliE7GAY7QtxkQzSTgkrKJ_TjFnUp5pygf4oh2Exdm4XZ69pMXRusTPmhon7z96RP2sdyCzDfAlC6uQmQTHYBRgc-JHBr42P4r6B72SjF8g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1937527248</pqid></control><display><type>article</type><title>Exosomal biomarkers in Down syndrome and Alzheimer's disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>SWEPUB Freely available online</source><creator>Hamlett, Eric D. ; Ledreux, Aurélie ; Potter, Huntington ; Chial, Heidi J. ; Patterson, David ; Espinosa, Joaquin M. ; Bettcher, Brianne M. ; Granholm, Ann-Charlotte</creator><creatorcontrib>Hamlett, Eric D. ; Ledreux, Aurélie ; Potter, Huntington ; Chial, Heidi J. ; Patterson, David ; Espinosa, Joaquin M. ; Bettcher, Brianne M. ; Granholm, Ann-Charlotte</creatorcontrib><description>Every person with Down syndrome (DS) has the characteristic features of Alzheimer's disease (AD) neuropathology in their brain by the age of forty, and most go on to develop AD dementia. Since people with DS show highly variable levels of baseline function, it is often difficult to identify early signs of dementia in this population. The discovery of blood biomarkers predictive of dementia onset and/or progression in DS is critical for developing effective clinical diagnostics. Our recent studies show that neuron-derived exosomes, which are small extracellular vesicles secreted by most cells in the body, contain elevated levels of amyloid-beta peptides and phosphorylated-Tau that could indicate a preclinical AD phase in people with DS starting in childhood. We also found that the relative levels of these biomarkers were altered following dementia onset. Exosome release and signaling are dependent on cellular redox homeostasis as well as on inflammatory processes, and exosomes may be involved in the immune response, suggesting a dual role as both triggers of inflammation in the brain and propagators of inflammatory signals between brain regions. Based on recently reported connections between inflammatory processes and exosome release, the elevated neuroinflammatory state observed in people with DS may affect exosomal AD biomarkers. Herein, we discuss findings from studies of people with DS, people with DS and AD (DS-AD), and mouse models of DS showing new connections between neuroinflammatory pathways, oxidative stress, exosomes, and exosome-mediated signaling, which may inform future AD diagnostics, preventions, and treatments in the DS population as well as in the general population. [Display omitted] •Exosome technology can detect AD biomarkers decades prior to the onset of symptoms.•Exosome signaling and release are affected by both oxidative homeostasis and inflammation.•Exosomes may deliver therapies targeting oxidative stress, inflammation, and brain pathology.</description><identifier>ISSN: 0891-5849</identifier><identifier>ISSN: 1873-4596</identifier><identifier>EISSN: 1873-4596</identifier><identifier>DOI: 10.1016/j.freeradbiomed.2017.08.028</identifier><identifier>PMID: 28882786</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Alzheimer Disease - diagnosis ; Alzheimer Disease - metabolism ; Alzheimer's disease ; Biomarkers - metabolism ; Down syndrome ; Down Syndrome - diagnosis ; Down Syndrome - metabolism ; Exosomes ; Exosomes - metabolism ; Humans ; Medicin och hälsovetenskap ; Neurodegeneration ; Neuroinflammation ; Oxidative stress</subject><ispartof>FREE RADICAL BIOLOGY AND MEDICINE, 2018-01, Vol.114, p.110-121</ispartof><rights>2017</rights><rights>Copyright © 2017. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c579t-76b19230b64deb02fabc469ae856a2d54ef71be685739a3eb02879dcdac1cda93</citedby><cites>FETCH-LOGICAL-c579t-76b19230b64deb02fabc469ae856a2d54ef71be685739a3eb02879dcdac1cda93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.freeradbiomed.2017.08.028$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,552,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28882786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:137352431$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Hamlett, Eric D.</creatorcontrib><creatorcontrib>Ledreux, Aurélie</creatorcontrib><creatorcontrib>Potter, Huntington</creatorcontrib><creatorcontrib>Chial, Heidi J.</creatorcontrib><creatorcontrib>Patterson, David</creatorcontrib><creatorcontrib>Espinosa, Joaquin M.</creatorcontrib><creatorcontrib>Bettcher, Brianne M.</creatorcontrib><creatorcontrib>Granholm, Ann-Charlotte</creatorcontrib><title>Exosomal biomarkers in Down syndrome and Alzheimer's disease</title><title>FREE RADICAL BIOLOGY AND MEDICINE</title><addtitle>Free Radic Biol Med</addtitle><description>Every person with Down syndrome (DS) has the characteristic features of Alzheimer's disease (AD) neuropathology in their brain by the age of forty, and most go on to develop AD dementia. Since people with DS show highly variable levels of baseline function, it is often difficult to identify early signs of dementia in this population. The discovery of blood biomarkers predictive of dementia onset and/or progression in DS is critical for developing effective clinical diagnostics. Our recent studies show that neuron-derived exosomes, which are small extracellular vesicles secreted by most cells in the body, contain elevated levels of amyloid-beta peptides and phosphorylated-Tau that could indicate a preclinical AD phase in people with DS starting in childhood. We also found that the relative levels of these biomarkers were altered following dementia onset. Exosome release and signaling are dependent on cellular redox homeostasis as well as on inflammatory processes, and exosomes may be involved in the immune response, suggesting a dual role as both triggers of inflammation in the brain and propagators of inflammatory signals between brain regions. Based on recently reported connections between inflammatory processes and exosome release, the elevated neuroinflammatory state observed in people with DS may affect exosomal AD biomarkers. Herein, we discuss findings from studies of people with DS, people with DS and AD (DS-AD), and mouse models of DS showing new connections between neuroinflammatory pathways, oxidative stress, exosomes, and exosome-mediated signaling, which may inform future AD diagnostics, preventions, and treatments in the DS population as well as in the general population. [Display omitted] •Exosome technology can detect AD biomarkers decades prior to the onset of symptoms.•Exosome signaling and release are affected by both oxidative homeostasis and inflammation.•Exosomes may deliver therapies targeting oxidative stress, inflammation, and brain pathology.</description><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer's disease</subject><subject>Biomarkers - metabolism</subject><subject>Down syndrome</subject><subject>Down Syndrome - diagnosis</subject><subject>Down Syndrome - metabolism</subject><subject>Exosomes</subject><subject>Exosomes - metabolism</subject><subject>Humans</subject><subject>Medicin och hälsovetenskap</subject><subject>Neurodegeneration</subject><subject>Neuroinflammation</subject><subject>Oxidative stress</subject><issn>0891-5849</issn><issn>1873-4596</issn><issn>1873-4596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNqNkc1uEzEUhS0EomnhFdBILGAzg3_HtkCVqpK2SJXYwNry2Heo08k42ElLefp6mrSQBRIb27K_c86VD0JvCW4IJu2HRdMngGR9F-ISfEMxkQ1WDabqGZoRJVnNhW6foxlWmtRCcX2ADnNeYIy5YOolOqBKKSpVO0Of5r9ijks7VJObTdeQchXG6nO8Hat8N_pUMio7-upk-H0FYQnpXa58yGAzvEIvejtkeL3bj9D3s_m304v68uv5l9OTy9oJqde1bDuiKcNdyz10mPa2c7zVFpRoLfWCQy9JB60SkmnLJkRJ7Z23jpRFsyNUb33zLaw2nVmlUEa9M9EGs7u6LicwXHOiVeH1P_lViv6P6FFImGSCckaK9nirLUD5XQfjOtlh32LvZQxX5ke8MS1hAj-Ev98ZpPhzA3ltliE7GAY7QtxkQzSTgkrKJ_TjFnUp5pygf4oh2Exdm4XZ69pMXRusTPmhon7z96RP2sdyCzDfAlC6uQmQTHYBRgc-JHBr42P4r6B72SjF8g</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Hamlett, Eric D.</creator><creator>Ledreux, Aurélie</creator><creator>Potter, Huntington</creator><creator>Chial, Heidi J.</creator><creator>Patterson, David</creator><creator>Espinosa, Joaquin M.</creator><creator>Bettcher, Brianne M.</creator><creator>Granholm, Ann-Charlotte</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20180101</creationdate><title>Exosomal biomarkers in Down syndrome and Alzheimer's disease</title><author>Hamlett, Eric D. ; Ledreux, Aurélie ; Potter, Huntington ; Chial, Heidi J. ; Patterson, David ; Espinosa, Joaquin M. ; Bettcher, Brianne M. ; Granholm, Ann-Charlotte</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c579t-76b19230b64deb02fabc469ae856a2d54ef71be685739a3eb02879dcdac1cda93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer's disease</topic><topic>Biomarkers - metabolism</topic><topic>Down syndrome</topic><topic>Down Syndrome - diagnosis</topic><topic>Down Syndrome - metabolism</topic><topic>Exosomes</topic><topic>Exosomes - metabolism</topic><topic>Humans</topic><topic>Medicin och hälsovetenskap</topic><topic>Neurodegeneration</topic><topic>Neuroinflammation</topic><topic>Oxidative stress</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hamlett, Eric D.</creatorcontrib><creatorcontrib>Ledreux, Aurélie</creatorcontrib><creatorcontrib>Potter, Huntington</creatorcontrib><creatorcontrib>Chial, Heidi J.</creatorcontrib><creatorcontrib>Patterson, David</creatorcontrib><creatorcontrib>Espinosa, Joaquin M.</creatorcontrib><creatorcontrib>Bettcher, Brianne M.</creatorcontrib><creatorcontrib>Granholm, Ann-Charlotte</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>FREE RADICAL BIOLOGY AND MEDICINE</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hamlett, Eric D.</au><au>Ledreux, Aurélie</au><au>Potter, Huntington</au><au>Chial, Heidi J.</au><au>Patterson, David</au><au>Espinosa, Joaquin M.</au><au>Bettcher, Brianne M.</au><au>Granholm, Ann-Charlotte</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exosomal biomarkers in Down syndrome and Alzheimer's disease</atitle><jtitle>FREE RADICAL BIOLOGY AND MEDICINE</jtitle><addtitle>Free Radic Biol Med</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>114</volume><spage>110</spage><epage>121</epage><pages>110-121</pages><issn>0891-5849</issn><issn>1873-4596</issn><eissn>1873-4596</eissn><abstract>Every person with Down syndrome (DS) has the characteristic features of Alzheimer's disease (AD) neuropathology in their brain by the age of forty, and most go on to develop AD dementia. Since people with DS show highly variable levels of baseline function, it is often difficult to identify early signs of dementia in this population. The discovery of blood biomarkers predictive of dementia onset and/or progression in DS is critical for developing effective clinical diagnostics. Our recent studies show that neuron-derived exosomes, which are small extracellular vesicles secreted by most cells in the body, contain elevated levels of amyloid-beta peptides and phosphorylated-Tau that could indicate a preclinical AD phase in people with DS starting in childhood. We also found that the relative levels of these biomarkers were altered following dementia onset. Exosome release and signaling are dependent on cellular redox homeostasis as well as on inflammatory processes, and exosomes may be involved in the immune response, suggesting a dual role as both triggers of inflammation in the brain and propagators of inflammatory signals between brain regions. Based on recently reported connections between inflammatory processes and exosome release, the elevated neuroinflammatory state observed in people with DS may affect exosomal AD biomarkers. Herein, we discuss findings from studies of people with DS, people with DS and AD (DS-AD), and mouse models of DS showing new connections between neuroinflammatory pathways, oxidative stress, exosomes, and exosome-mediated signaling, which may inform future AD diagnostics, preventions, and treatments in the DS population as well as in the general population. [Display omitted] •Exosome technology can detect AD biomarkers decades prior to the onset of symptoms.•Exosome signaling and release are affected by both oxidative homeostasis and inflammation.•Exosomes may deliver therapies targeting oxidative stress, inflammation, and brain pathology.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28882786</pmid><doi>10.1016/j.freeradbiomed.2017.08.028</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0891-5849
ispartof FREE RADICAL BIOLOGY AND MEDICINE, 2018-01, Vol.114, p.110-121
issn 0891-5849
1873-4596
1873-4596
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_494198
source MEDLINE; Elsevier ScienceDirect Journals Complete; SWEPUB Freely available online
subjects Alzheimer Disease - diagnosis
Alzheimer Disease - metabolism
Alzheimer's disease
Biomarkers - metabolism
Down syndrome
Down Syndrome - diagnosis
Down Syndrome - metabolism
Exosomes
Exosomes - metabolism
Humans
Medicin och hälsovetenskap
Neurodegeneration
Neuroinflammation
Oxidative stress
title Exosomal biomarkers in Down syndrome and Alzheimer's disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A57%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exosomal%20biomarkers%20in%20Down%20syndrome%20and%20Alzheimer's%20disease&rft.jtitle=FREE%20RADICAL%20BIOLOGY%20AND%20MEDICINE&rft.au=Hamlett,%20Eric%20D.&rft.date=2018-01-01&rft.volume=114&rft.spage=110&rft.epage=121&rft.pages=110-121&rft.issn=0891-5849&rft.eissn=1873-4596&rft_id=info:doi/10.1016/j.freeradbiomed.2017.08.028&rft_dat=%3Cproquest_swepu%3E1937527248%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1937527248&rft_id=info:pmid/28882786&rft_els_id=S089158491730744X&rfr_iscdi=true